The urinary dehydroepiandrosterone, androsterone and etiocholanolone excretion of healthy women and women with benign and malignant breast disease
Само за регистроване кориснике
1990
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The 24‐h urinary excretion of dehydroepiandrosterone, androsterone and etiocholanolone was followed in healthy women (n = 50) and in women with benign‐fibroadenoma (w = 32), microcysts (n= 32), macrocysts (n= 25) and malignant (n = 35) breast disease aged 35–50‐years. The data were analysed in three groups each covering 5 years (35‐39, 40–44 and 45–49). A significant decrease in the excretion of ethiocholanolone and dehydroepiandrosterone was found in women with benign and malignant breast disease when compared to controls. There was no significant decrease in androsterone excretion in women with benign and malignant breast disease when compared to a control group. A high correlation was found between excretion of etiocholanolone and its precursor dehydroepiandrosterone both in women with benign‐fibroadenoma (r= 0–7683) or macrocysts (r= 0–7337) and in women with malignant (r= 0–805) breast disease. Dehydroepiandrosterone and, in particular, etiocholanolone excretions were found to dec...rease significantly with age in women affected by malignant breast disease.
Извор:
Journal of Clinical Pharmacy and Therapeutics, 1990, 15, 3, 213-219
DOI: 10.1111/j.1365-2710.1990.tb00377.x
ISSN: 0269-4727
Scopus: 2-s2.0-0025012169
Институција/група
PharmacyTY - JOUR AU - Ivanović, S AU - Agbaba, Danica AU - Živanov-Stakić, Dobrila AU - Konstantinović, I PY - 1990 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/74 AB - The 24‐h urinary excretion of dehydroepiandrosterone, androsterone and etiocholanolone was followed in healthy women (n = 50) and in women with benign‐fibroadenoma (w = 32), microcysts (n= 32), macrocysts (n= 25) and malignant (n = 35) breast disease aged 35–50‐years. The data were analysed in three groups each covering 5 years (35‐39, 40–44 and 45–49). A significant decrease in the excretion of ethiocholanolone and dehydroepiandrosterone was found in women with benign and malignant breast disease when compared to controls. There was no significant decrease in androsterone excretion in women with benign and malignant breast disease when compared to a control group. A high correlation was found between excretion of etiocholanolone and its precursor dehydroepiandrosterone both in women with benign‐fibroadenoma (r= 0–7683) or macrocysts (r= 0–7337) and in women with malignant (r= 0–805) breast disease. Dehydroepiandrosterone and, in particular, etiocholanolone excretions were found to decrease significantly with age in women affected by malignant breast disease. T2 - Journal of Clinical Pharmacy and Therapeutics T1 - The urinary dehydroepiandrosterone, androsterone and etiocholanolone excretion of healthy women and women with benign and malignant breast disease VL - 15 IS - 3 SP - 213 EP - 219 DO - 10.1111/j.1365-2710.1990.tb00377.x ER -
@article{ author = "Ivanović, S and Agbaba, Danica and Živanov-Stakić, Dobrila and Konstantinović, I", year = "1990", abstract = "The 24‐h urinary excretion of dehydroepiandrosterone, androsterone and etiocholanolone was followed in healthy women (n = 50) and in women with benign‐fibroadenoma (w = 32), microcysts (n= 32), macrocysts (n= 25) and malignant (n = 35) breast disease aged 35–50‐years. The data were analysed in three groups each covering 5 years (35‐39, 40–44 and 45–49). A significant decrease in the excretion of ethiocholanolone and dehydroepiandrosterone was found in women with benign and malignant breast disease when compared to controls. There was no significant decrease in androsterone excretion in women with benign and malignant breast disease when compared to a control group. A high correlation was found between excretion of etiocholanolone and its precursor dehydroepiandrosterone both in women with benign‐fibroadenoma (r= 0–7683) or macrocysts (r= 0–7337) and in women with malignant (r= 0–805) breast disease. Dehydroepiandrosterone and, in particular, etiocholanolone excretions were found to decrease significantly with age in women affected by malignant breast disease.", journal = "Journal of Clinical Pharmacy and Therapeutics", title = "The urinary dehydroepiandrosterone, androsterone and etiocholanolone excretion of healthy women and women with benign and malignant breast disease", volume = "15", number = "3", pages = "213-219", doi = "10.1111/j.1365-2710.1990.tb00377.x" }
Ivanović, S., Agbaba, D., Živanov-Stakić, D.,& Konstantinović, I.. (1990). The urinary dehydroepiandrosterone, androsterone and etiocholanolone excretion of healthy women and women with benign and malignant breast disease. in Journal of Clinical Pharmacy and Therapeutics, 15(3), 213-219. https://doi.org/10.1111/j.1365-2710.1990.tb00377.x
Ivanović S, Agbaba D, Živanov-Stakić D, Konstantinović I. The urinary dehydroepiandrosterone, androsterone and etiocholanolone excretion of healthy women and women with benign and malignant breast disease. in Journal of Clinical Pharmacy and Therapeutics. 1990;15(3):213-219. doi:10.1111/j.1365-2710.1990.tb00377.x .
Ivanović, S, Agbaba, Danica, Živanov-Stakić, Dobrila, Konstantinović, I, "The urinary dehydroepiandrosterone, androsterone and etiocholanolone excretion of healthy women and women with benign and malignant breast disease" in Journal of Clinical Pharmacy and Therapeutics, 15, no. 3 (1990):213-219, https://doi.org/10.1111/j.1365-2710.1990.tb00377.x . .